2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione Chemical Properties

Melting point:

208-211°C

Boiling point:

734.9±60.0 °C(Predicted)

Density 

1.421

storage temp. 

under inert gas (nitrogen or Argon) at 2–8 °C

solubility 

DMSO (Slightly), Methanol (Slightly, Heated)

pka

13.91±0.20(Predicted)

form 

Solid

color 

White to Off-White

Water Solubility 

37mg/L at 20℃

InChI

InChI=1S/C21H21N3O5/c25-16(12-24-20(27)17-3-1-2-4-18(17)21(24)28)11-22-14-5-7-15(8-6-14)23-9-10-29-13-19(23)26/h1-8,16,22,25H,9-13H2/t16-/m1/s1

InChIKey

CKFVSMPWXAASIQ-MRXNPFEDSA-N

SMILES

C1(=O)C2=C(C=CC=C2)C(=O)N1C[C@H](O)CNC1=CC=C(N2CCOCC2=O)C=C1

LogP

0.6 at 25℃

CAS DataBase Reference

446292-07-5

Safety Information

HS Code 

2922498590

2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione Usage And Synthesis

Chemical Properties

White Solid

Uses

4-[((2R)-Hydroxy-3-phthalimido)propylamine]phenyl-3-morpholinone is a Rivaroxaban (R538000(P)) intermediate. Rivaroxaban is a novel antithrombotic agent. It is also a highly potent and selective, direct FXa inhibitor.

Uses

Rivaroxaban intermediate.

Flammability and Explosibility

Non flammable

Synthesis

Example 3: Preparation of (R)-2-(2-hydroxy-3-((4-(3-oxomorpholinyl)phenyl)amino)propyl)isoindoline-1,3-dione (7a): phthalimide potassium salt (7.16 g, 38.632 mmol) was added in a single addition to a mechanically stirred N,N-dimethylformamide (DMF, 60 mL) solution of 4-[4-(N-(3-chloro-2R-hydroxy-1-propyl)amino)phenyl]morpholine -3-one (10 g, 35.119 mmol) in a solution of N,N-dimethylformamide (DMF, 60 mL). After stirring the suspension at room temperature, it was heated to 100 °C and stirred continuously at this temperature for 3 hours. After the reaction was completed, the mixture was cooled to room temperature. Water (60 mL) was added and the suspension continued to be stirred for 15 minutes. Subsequently, the suspension was filtered through a Brinell funnel and the solid product was collected. The solid was washed with distilled water (2 x 40 mL) and dried under vacuum at 50 °C for 10 h to afford the target product (R)-2-(2-hydroxy-3-((4-(3-oxomorpholinyl)phenyl)amino)propyl)isoindoline-1,3-dione (12.55 g, 93% yield) as a white crystalline solid.1H NMR (400 MHz, DMSO-d6) δ. 2.99-3.05 (m, 1H), 3.14-3.2 (m, 1H), 3.59-3.69 (m, 4H), 3.91-3.94 (m, 2H), 3.97-4.05 (m, 1H), 4.14 (s, 2H), 5.16 (d, J = 5.2 Hz, 1H), 5.66 (t, J = 6.0 Hz, 1H), 6.61 (d, J = 6.0 Hz, 1H), 6.61 (d, J = 6.0 Hz, 1H). 6.61 (d, J = 8.7 Hz, 2H), 7.03 (d, J = 8.8 Hz, 2H), 7.82-7.88 (m, 4H).

References

[1] Patent: WO2012/51692, 2012, A1. Location in patent: Page/Page column 42-43
[2] Patent: CN103951661, 2017, B. Location in patent: Paragraph 0043-0044
[3] Patent: CN104974105, 2017, B. Location in patent: Paragraph 0073
[4] Patent: CN104974149, 2018, B. Location in patent: Paragraph 0074; 0075; 0077; 0081; 0083
[5] Patent: WO2012/32533, 2012, A2. Location in patent: Page/Page column 15

2-[(2R)-2-Hydroxy-3-[[4-(3-oxo-4-Morpho linyl)phenyl]aMino]propyl]-1H-isoindole-1 ,3(2H)-dione(446292-07-5)Related Product Information

• 1,2-BenzenedicarboxaMide, N1,N2-bis[[(5S)-2-oxo-3-[4-(3-oxo-4-Morpholinyl)phenyl]-5-oxazolidinyl]Methyl]-
• 2-QuinazolineMethanol, 4-Methyl-
• Rivaroxaban Impurity 34
• (R)-N-Glycidylphthalimide
• 4,5-DICHLOROTHIOPHENE-2-CARBOXYLIC ACID
• 2-Thiophenecarboxylic acid
• 1H-ISOINDOLE-1,3(2H)-DIONE, 2-[[(5S)-2-OXO-3-[4-(3-OXO-4-MORPHOLINYL)PHENYL]-5-OXAZOLIDINYL]METHYL]-
• Rivaroxaban
• POLYSTYRENE IODOSOACETATE
• 1,2-Cyclohexanedione
• 4-(4-NITROPHENYL)MORPHOLIN-3-ONE
• (S)-(+)-Glycidyl Phthalimide
• 4-[4-(N-(3-chloro-(2R)-2-hydroxy-1-propyl)aMino)phenyl]Morpholin-3-one
• (S)-4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one.HCl
• 5-CHLOROTHIOPHENE-2-CARBONYL CHLORIDE
• Ethyl (R)-(-)-4-cyano-3-hydroxybutyate
• 3-MORPHOLINONE, 4-[4-[(5S)-5-(AMINOMETHYL)-2-OXO-3-OXAZOLIDINYL]PHENYL]-
• (S)-(+)-Epichlorohydrin